In this study we evaluated UCN-01, a small molecule that inhibits protein kinases by interacting with the ATP-binding site, as a potential anti-cancer agent for neuroblastoma. UCN-01 was effective at inducing apoptosis in six neuroblastoma cell lines with diverse cellular and genetic phenotypes. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), terminal deoxynucleotidyl transferase-mediated dUTP nickend-labeling (TUNEL) assays, detection of active caspase-3 and cleaved poly ADP-ribose polymerase (PARP) confirmed that UCN-01 induced apoptosis. Cell cycle analysis determined that the UCN-01 treated cells accumulated in S phase by 16 h. Unlike vinblastine and docetaxel that increased survivin expression, UCN-01 treatment did not increase X-linked inhibitor of apoptosis protein (XIAP) and survivin levels. Analysis of specific phosphoepitopes on chk1/2, Akt, and GSK3b following UCN-01 treatment determined that there was no significant change in phospho-chk1/2. However, there was decreased immunoreactivity at Ser473 and Thr308 of Akt and Ser9 of GSK3b by 4 h indicating that the Akt survival pathway and downstream signalling was compromised. Thus, UCN-01 was effective at inducing apoptosis in neuroblastoma cell lines. Keywords: Akt, apoptosis, GSK3b, neuroblastomas, staurosporine, survivin, 7-hydroxystaurosporine (UCN-01). Neuroblastoma is the most common malignancy of infancy and constitutes 50% of all childhood cancers (Gale et al. 1982;Young et al. 1986;Taylor and Locker 1990;Brodeur and Castleberry 1997). Some neuroblastomas may be cured by minimal therapy; however, there is no effective treatment for many advanced and metastatic neuroblastomas (Brodeur and Castleberry 1997). In addition, present treatments for neuroblastoma have significant morbidity (Brodeur and Castleberry 1997). Among the specific biological abnormalities that correlate with poor clinical outcome and aggressiveness of the tumor are nuclear DNA content, near diploidy or tetraploidy (Taylor et al. 1988;Taylor and Locker 1990;Gestblom et al. 1995), deletion of the short arm of chromosome 1 (1p) (Westermann and Schwab 2002), N-myc amplification (Taylor and Locker 1990), loss of Bcl-2 (Reed et al. 1991), insensitivity to radiation (Halperin et al. 1999), and increased expression of the inhibitor-of-apoptosis (IAP) family member, survivin (Adida et al. 1998;Azuhata et al. 2001). While these factors predict therapeutic outcome, there are specific biological determinants, such as components of the apoptotic cascade, that may be prognostic indicators for drug resistance (Emran et al. 2002;Gallo et al. 2003;Iolascon et al. 2003). Therefore, new and novel therapies with a biological rationale are urgently needed for this fatal disease.Members of the IAP family bind to and inhibit caspases and suppress cell death in cancer. Presently, there are eight mammalian IAP family members that include survivin, neuronal apoptosis inhibitor protein (NAIP), BIR-repeatcontaining ubiquitin-conjugating enzyme (BRUCE), livin, ILP-2, cIAP-1, cIAP-...